Optimized human cell products for research
and drug discovery

Platform Technology

OptiDIFF best-in-class hIPSC platform technology produces liver, pancreatic, lung and intestinal cells

Human Induced Pluripotent Stem Cell (hIPSC) production was first demonstrated in 2007 and has aroused great scientific, social, and economic interest earning Shinya Yamanaka the Nobel Prize in 2012. OptiDIFF™ our proprietary core technology is a world-leading production platform developed at the University of Cambridge for the generation of hIPSC, and their differentiation into commercially prioritised cell types including liver, pancreatic, lung, and intestinal cells. The platform uses GMP-compatible defined conditions which enables the exquisite quantitative and temporal process control required to produce standardized populations of terminally differentiated cell products with typical production runs generating several billions of cells. Crucially these cell products are cryopreserved to provide industrial quantities of cells to clients in a manner which enable workflow optimization. The platform was first used to generate liver hepatocytes, on which a range of genetic diseases were modelled successfully and in a ground-breaking development the platform can now generate pancreatic beta cells that exhibit glucose responsive insulin production in response to the main classes of diabetes drugs. The OptiDIFF platform can be used to generate client-specified custom disease models for a variety of indications ranging from orphan liver and metabolic diseases to type one and type 2 patient-derived diabetes models.

Definigen OptiDIFF Platform

  1. Generation of Hepatocytes from Pluripotent Stem Cells for Drug Screening and Developmental Modeling. Gieseck RL 3rd, Vallier L, Hannan NR. Methods Mol Biol. 2015;1250:123-42.
  2. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Sampaziotis F, Vallier L et al Nature Biotechnol. 2015 Aug; 33(8): 845–852.
  3. Generation of Distal Airway Epithelium from Multipotent Human Foregut Stem Cells. Hannan NR, Sampaziotis F, Segeritz CP, Hanley NA, Vallier L. Stem Cells Dev. 2015 Jul 15;24(14):1680-90.
  4. Production of hepatocyte-like cells from human pluripotent stem cells. Hannan NR, Vallier L et al. Nature Protocols.2013 Feb;8(2):430-7.
  5. Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells. Cho C , Hannan NR, Vallier L et al. Diabetologia. 2012 Dec 55(12):3284-95.
  6. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Yusa K, Rashid ST, Vallier L et al. Nature. 2011 Oct 12;478(7369):391-4.
  7. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Rashid ST, Lomas DA, Vallier L et al. J Clin Invest. 2010 Sep;120(9):3127-36.

Contact us to find out more

Please provide brief description here.